Cancer Stem Cells: From Bench to Bedside

Biology of Blood and Marrow Transplantation

Volumn 13, Issue SUPPL. 1, 2007, Pages 47-52

  Jones, Richard J ^a   Matsui, William ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cancer stem cells; Imatinib; Leukemia; Multiple myeloma

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BORTEZOMIB; CALICHEAMICIN; GAMMA INTERFERON; GEMTUZUMAB OZOGAMICIN; IMATINIB; LENALIDOMIDE; RITUXIMAB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER REGRESSION; CELL DIFFERENTIATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOLOGY; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; GENETIC RESISTANCE; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MYELOMA; OVERALL SURVIVAL; STEM CELL;

EID: 33845996567     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2006.10.010     Document Type: Article

References (60)

1. Park C.H., Bergsagel D.E., and McCulloch E.A. Mouse myeloma tumor stem cells: a primary cell culture assay. J Natl Cancer Inst 46 (1971) 411-422
2. Hamburger A.W., and Salmon S.E. Primary bioassay of human tumor stem cells. Science 197 (1977) 461-463
3. Fialkow P.J., Gartler S.M., and Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 58 (1967) 1468-1471
4. Bedi A., Zehnbauer B.A., Collector M.I., et al. BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 81 (1993) 2898-2902
5. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367 (1994) 645-648
6. Sirard C., Lapidot T., Vormoor J., et al. Normal and leukemic SCID-repopulating cells (SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic phase, whereas leukemic SRC are detected in blast crisis. Blood 87 (1996) 1539-1548
7. Nilsson L., Astrand-Grundstrom I., Anderson K., et al. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8. Blood 100 (2002) 259-267
8. Al Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., and Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100 (2003) 3983-3988
9. Matsui W.H., Huff C.A., Wang Q., et al. Characterization of clonogenic multiple myeloma cells. Blood 103 (2004) 2332-2336
10. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 63 (2003) 5821-5828
11. Hemmati H.D., Nakano I., Lazareff J.A., et al. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100 (2003) 15178-15183
12. Kim C.F., Jackson E.L., Woolfenden A.E., et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121 (2005) 823-835
13. Huff C.A., Matsui W., Smith B.D., and Jones R.J. The paradox of response and survival in cancer therapeutics. Blood 107 (2006) 431-434
14. Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (1993) 75-88
15. Durie B.G., Jacobson J., Barlogie B., and Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 22 (2004) 1857-1863
16. Attal M., Harousseau J.L., Stoppa A.M., et al., Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
17. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
18. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 24 (2006) 929-936
19. Levy V., Katsahian S., Fermand J.P., Mary J.Y., and Chevret S. A meta-analysis on data from 575 patients with multiple myeloma randomly assigned to either high-dose therapy or conventional therapy. Medicine (Baltimore) 84 (2005) 250-259
20. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
21. Trump D., and Lau Y.K. Chemotherapy of prostate cancer: present and future. Curr Urol Rep 4 (2003) 229-232
22. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
23. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
24. Roy L., Guilhot J., Krahnke T., et al. Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108 (2006) 1478-1484
25. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
26. Merante S., Orlandi E., Bernasconi P., Calatroni S., Boni M., and Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90 (2005) 979-981
27. Mauro M.J., Druker B.J., and Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28 suppl 1 (2004) S71-S73
28. Mauro M.J., Druker B.J., Kuyl J., Kurilik G., and Maziarz R.T. Increasing levels of detectable leukemia in imatinib treated CML patients with previously undetectable or very low levels of BCR-ABL. Proc ASCO 22 (2003) 569
29. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
30. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
31. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
32. Holtz M.S., Slovak M.L., Zhang F., Sawyers C.L., Forman S.J., and Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 99 (2002) 3792-3800
33. Angstreich G.R., Matsui W., Huff C.A., et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 130 (2005) 373-381
34. Raaijmakers M.H., van Emst L., De Witte T., Mensink E., and Raymakers R.A. Quantitative assessment of gene expression in highly purified hematopoietic cells using real-time reverse transcriptase polymerase chain reaction. Exp Hematol 30 (2002) 481-487
35. Bunting K.D. ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 20 (2002) 11-20
36. Burger H., van Tol H., Boersma A.W., et al. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104 (2004) 2940-2942
37. Mahon F.X., Belloc F., Lagarde V., et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 101 (2003) 2368-2373
38. Jamieson C.H., Ailles L.E., Dylla S.J., et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 351 (2004) 657-667
39. Jiang G., Yang F., Li M., et al. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. Cancer Biol Ther 2 (2003) 103-108
40. Jones R.J., Matsui W.H., and Smith B.D. Cancer stem cells: are we missing the target?. J Natl Cancer Inst 96 (2004) 583-585
41. Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 98 (2001) 3074-3081
42. Pierce A., Smith D.L., Jakobsen L.V., Whetton A.D., and Spooncer E. The specific enhancement of interferon alpha induced growth inhibition by BCR/ABL only occurs in multipotent cells. Hematol J 2 (2001) 257-264
43. Matsui W., Huff C.A., Wang Q., Barber J.P., Smith B.D., and Jones R.J. Multiple myeloma stem cells and plasma cells display distinct drug sensitivities. Blood 104 (2004) 679a
44. Treon S.P., Pilarski L.M., Belch A.R., et al. CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother 25 (2002) 72-81
45. Wittebol S., Raymakers R., van de Locht L., Mensink E., and De Witte T. In AML t(8;21) colony growth of both leukemic and residual normal progenitors is restricted to the CD34+, lineage-negative fraction. Leukemia 12 (1998) 1782-1788
46. Uckun F.M., Messinger Y., Chen C.L., et al. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor. Clin Cancer Res 5 (1999) 3906-3913
47. Szatrowski T.P., Dodge R.K., Reynolds C., et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311. Cancer 97 (2003) 1471-1480
48. Quijano C.A., Moore D., Arthur D., Feusner J., Winter S.S., and Pallavicini M.G. Cytogenetically aberrant cells are present in the CD34+CD33-38-19- marrow compartment in children with acute lymphoblastic leukemia. Leukemia 11 (1997) 1508-1515
49. Hotfilder M., Rottgers S., Rosemann A., et al. Leukemic stem cells in childhood high-risk ALL/t(9;22) and t(4;11) are present in primitive lymphoid-restricted CD34+19- cells. Cancer Res 65 (2005) 1442-1449
50. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
51. Harrington L. Does the reservoir for self-renewal stem from the ends?. Oncogene 23 (2004) 7283-7289
52. Hao L.Y., Armanios M., Strong M.A., et al. Short telomeres, even in the presence of telomerase, limit tissue renewal capacity. Cell 123 (2005) 1121-1131
53. Dokal I., and Vulliamy T. Dyskeratosis congenita: its link to telomerase and aplastic anaemia. Blood Rev 17 (2003) 217-225
54. Greenberg R.A., Chin L., Femino A., et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 97 (1999) 515-525
55. Rudolph K.L., Millard M., Bosenberg M.W., and DePinho R.A. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 28 (2001) 155-159
56. Goodell M.A., Rosenzweig M., Kim H., et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 3 (1997) 1337-1345
57. Brodsky R.A., and Jones R.J. Aplastic anaemia. Lancet 365 (2005) 1647-1656
58. Jones R.J., Barber J.P., Vala M.S., et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 85 (1995) 2742-2746
59. Corti S., Locatelli F., Papadimitriou D., et al. Identification of a primitive brain-derived neural stem cell population based on aldehyde dehydrogenase activity. Stem Cells 24 (2006) 975-985
60. Hirschmann-Jax C., Foster A.E., Wulf G.G., et al. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101 (2004) 14228-14233